AU2009212079B2 - Antigen-binding polypeptides against cartilage degeneration - Google Patents

Antigen-binding polypeptides against cartilage degeneration Download PDF

Info

Publication number
AU2009212079B2
AU2009212079B2 AU2009212079A AU2009212079A AU2009212079B2 AU 2009212079 B2 AU2009212079 B2 AU 2009212079B2 AU 2009212079 A AU2009212079 A AU 2009212079A AU 2009212079 A AU2009212079 A AU 2009212079A AU 2009212079 B2 AU2009212079 B2 AU 2009212079B2
Authority
AU
Australia
Prior art keywords
antigen
polypeptide
cartilage
binding polypeptide
anyone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009212079A
Other languages
English (en)
Other versions
AU2009212079A1 (en
Inventor
Peter Lichtlen
David Urech
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Delenex Therapeutics AG
Original Assignee
Delenex Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delenex Therapeutics AG filed Critical Delenex Therapeutics AG
Publication of AU2009212079A1 publication Critical patent/AU2009212079A1/en
Application granted granted Critical
Publication of AU2009212079B2 publication Critical patent/AU2009212079B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2009212079A 2008-02-05 2009-02-05 Antigen-binding polypeptides against cartilage degeneration Ceased AU2009212079B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2631708P 2008-02-05 2008-02-05
US61/026,317 2008-02-05
US8887608P 2008-08-14 2008-08-14
US61/088,876 2008-08-14
PCT/CH2009/000045 WO2009097704A1 (en) 2008-02-05 2009-02-05 Antigen-binding polypeptides against cartilage degeneration

Publications (2)

Publication Number Publication Date
AU2009212079A1 AU2009212079A1 (en) 2009-08-13
AU2009212079B2 true AU2009212079B2 (en) 2012-08-30

Family

ID=40568129

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009212079A Ceased AU2009212079B2 (en) 2008-02-05 2009-02-05 Antigen-binding polypeptides against cartilage degeneration

Country Status (10)

Country Link
US (1) US20110002927A1 (OSRAM)
EP (1) EP2240515A1 (OSRAM)
JP (1) JP2011510667A (OSRAM)
CN (1) CN101939335B (OSRAM)
AU (1) AU2009212079B2 (OSRAM)
BR (1) BRPI0907485A2 (OSRAM)
CA (1) CA2712965A1 (OSRAM)
IL (1) IL206720A0 (OSRAM)
RU (1) RU2010136988A (OSRAM)
WO (1) WO2009097704A1 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013540757A (ja) 2010-09-24 2013-11-07 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド カプセル化された作用物質の放出を制御する能力を有するナノ構造ゲル
CN104231086B (zh) * 2013-08-27 2019-12-13 北京韩美药品有限公司 双功能融合蛋白及其制备方法和用途
JP6220894B2 (ja) * 2013-12-13 2017-10-25 有限会社マーキュリーアセットマネジメント 関節軟骨の変性部位の可視化用組成物
WO2017193139A1 (en) * 2016-05-06 2017-11-09 The Brigham And Women's Hospital, Inc. Binary self assembled gels for controlled delivery of encapsulated agents to cartilage
EP3863602A1 (en) 2018-10-11 2021-08-18 Alivio Therapeutics, Inc. Non-injectable hydrogel formulations for smart release

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006131013A2 (en) * 2005-06-07 2006-12-14 Esbatech Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
WO2008006235A2 (en) * 2006-07-10 2008-01-17 Esbatech Ag Scfv antibodies which pass epithelial and/or endothelial layers

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006131013A2 (en) * 2005-06-07 2006-12-14 Esbatech Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
WO2008006235A2 (en) * 2006-07-10 2008-01-17 Esbatech Ag Scfv antibodies which pass epithelial and/or endothelial layers

Also Published As

Publication number Publication date
CN101939335A (zh) 2011-01-05
CN101939335B (zh) 2015-02-11
US20110002927A1 (en) 2011-01-06
IL206720A0 (en) 2010-12-30
RU2010136988A (ru) 2012-03-20
BRPI0907485A2 (pt) 2015-08-04
CA2712965A1 (en) 2009-08-13
AU2009212079A1 (en) 2009-08-13
EP2240515A1 (en) 2010-10-20
WO2009097704A1 (en) 2009-08-13
JP2011510667A (ja) 2011-04-07

Similar Documents

Publication Publication Date Title
JP6779944B2 (ja) 血漿カリクレイン結合タンパク質
KR102249078B1 (ko) 요법에 사용하기 위한 항-아드레노메둘린 (adm) 항체 또는 항-adm 항체 단편 또는 항-adm 비-ig 스캐폴드
ES2363162T3 (es) Composicones y procedimientos para el tratamiento de trastornos fibróticos.
Urech et al. Anti-inflammatory and cartilage-protecting effects of an intra-articularly injected anti-TNFα single-chain Fv antibody (ESBA105) designed for local therapeutic use
Kimmerling et al. Sustained intra-articular delivery of IL-1RA from a thermally-responsive elastin-like polypeptide as a therapy for post-traumatic arthritis
Moltó et al. Anti-IL-1 molecules: new comers and new indications
JP5022216B2 (ja) 自己炎症性疾患を処置するためのｉｌ−１アンタゴニストを使用する方法
JP7558900B2 (ja) 化膿性汗腺炎の治療に使用するための抗ｃｄ４０抗体
AU2009212079B2 (en) Antigen-binding polypeptides against cartilage degeneration
JP7008023B2 (ja) 低減されたポリソルベート分解を有する製剤
JP2017155051A (ja) 慢性若しくは急性疾患又は急性病態に罹患している患者の臓器機能障害又は臓器不全を予防又は軽減するための、抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場
JP2021181487A (ja) 新規な抗ｃｄ３抗体およびその使用
Pasi et al. Novel multimeric IL-1 receptor antagonist for the treatment of rheumatoid arthritis
EP3057992B1 (en) Human antibody against aggrecanase-type adamts species for therapeutics of aggrecanase-related diseases
Zhang et al. A novel single domain bispecific antibody targeting VEGF and TNF-α ameliorates rheumatoid arthritis
CN100500209C (zh) Clk-肽和slk-肽
WO2002070009A1 (en) Preventives/remedies for thickened scar, keloid or chronic arthritic diseases
Coll Therapeutic targeting of inflammasome signaling by blocking interleukin-1
KR20010024549A (ko) Ｔｎｆ 길항제의 패혈증 치료를 위한 약제로서의 용도
EP4392051A1 (en) Leukocyte-specific cell penetrating molecules
Urech et al. Anti-inflammatory and cartilage-protecting effects of an intra-articularly injected anti-TNF-α scFv (ESBA105) designed for local therapeutic use
TW201946652A (zh) 康納單抗(canakinumab)之用途
CN117355323A (zh) 用于治疗骨关节炎的方法
WO2020000063A1 (en) Rheumatoid arthritis treatment
NZ624869A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired